Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) AI Stock Analysis

• Market Cap: HK$10.67B
• Dividend Yield: 0.77%
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): 26.7
• Beta (1Y): 1.19
• Revenue Growth: 14.56%
• EPS Growth: 61.60%
• Country: HK
• Employees: 1,237
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.22
• Shares Outstanding: 95,140,500
• 10 Day Avg. Volume: 978,626
• 30 Day Avg. Volume: 1,198,522
• PEG Ratio: -0.45
• Price to Book (P/B): 1.08
• Price to Sales (P/S): 3.77
• P/FCF Ratio: -59.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: HK$17.00 ▼(-7.56% Downside)

The stock's overall score is primarily influenced by its strong technical analysis indicators, suggesting positive momentum. However, financial performance concerns, particularly in revenue and cash flow, and a high P/E ratio indicating potential overvaluation, weigh down the score.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Beijing Chunlizhengda Medical Instruments Co., Ltd. is a leading manufacturer and supplier in the medical device sector, specializing in the research, development, and production of a wide range of medical instruments. The company focuses on high-quality, innovative products used in various medical applications, including orthopedics, rehabilitation, and surgical procedures. With a commitment to advancing healthcare technology, Chunlizhengda aims to enhance patient outcomes through its cutting-edge medical solutions.

How the Company Makes Money

The company's revenue model primarily revolves around the sale of medical instruments and devices to hospitals, clinics, and healthcare providers both domestically and internationally. Key revenue streams include direct sales of orthopedic implants, surgical instruments, and rehabilitation equipment. Additionally, the company may generate income through partnerships with healthcare institutions for product development and distribution. Significant factors contributing to its earnings include a strong reputation for quality, compliance with medical regulations, and ongoing research and development efforts to innovate and expand its product line.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview

Summary

The company shows strong balance sheet stability with minimal debt levels. However, the significant decline in revenue and profitability margins, along with negative cash flow from operations, indicate potential financial stress. Improvements in revenue generation and operational cash flows are necessary for long-term growth.

Income Statement

The gross profit margin remains strong at 64.08% in 2024, indicating efficient cost management in production. However, revenue showed a significant decline of 33.33% from 2023 to 2024, indicating challenges in maintaining sales volumes. The net profit margin also decreased, reflecting reduced profitability. EBIT and EBITDA margins have also decreased, suggesting pressures on operational efficiency.

Balance Sheet

The company maintains a solid equity position with a debt-to-equity ratio of 0.0003, indicating minimal leverage and financial risk. The equity ratio is robust at 81.38%, showcasing strong financial stability. Despite a slight drop in stockholders' equity, the company's balance sheet remains strong.

Cash Flow

The operating cash flow turned negative in 2024, indicating issues in cash generation from core operations. Free cash flow has also declined, pointing to challenges in maintaining liquidity. The free cash flow to net income ratio is negative, highlighting the need for cash management improvements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	913.32M	805.86M	1.21B	1.20B	1.11B	937.69M
Gross Profit	550.05M	516.49M	875.89M	913.53M	854.54M	680.76M
EBITDA	178.05M	169.32M	340.65M	366.96M	360.99M	349.78M
Net Income	160.43M	124.99M	277.82M	307.72M	322.36M	283.37M
Balance Sheet
Total Assets	3.49B	3.47B	3.65B	3.41B	3.00B	1.54B
Cash, Cash Equivalents and Short-Term Investments	2.00B	1.89B	2.10B	1.72B	1.74B	690.12M
Total Debt	252.57K	866.44K	1.75M	1.31M	1.23M	1.85M
Total Liabilities	579.70M	644.39M	770.33M	690.07M	530.58M	460.41M
Stockholders Equity	2.91B	2.82B	2.88B	2.72B	2.47B	1.08B
Cash Flow
Free Cash Flow	151.20M	-51.07M	478.47M	16.10M	-34.62M	236.68M
Operating Cash Flow	208.64M	-1.90M	511.71M	41.01M	164.79M	260.68M
Investing Cash Flow	-165.47M	55.84M	-81.56M	-762.61M	―	-21.54M
Financing Cash Flow	-191.20M	-183.14M	-121.33M	―	1.07B	-11.88M

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.39
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Positive. The current price of 18.39 is above the 20-day moving average (MA) of 17.02, above the 50-day MA of 16.43, and above the 200-day MA of 12.40, indicating a bullish trend. The MACD of 0.80 indicates Negative momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 54.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1858.

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1763	75 Outperform	HK$6.69B	14.59	8.59%	2.76%	13.59%	6.31%
1789	69 Neutral	HK$6.49B	20.29	11.24%	1.25%	25.18%	55.79%
1858	62 Neutral	HK$10.67B	26.67	8.69%	0.77%	14.56%	61.60%
2190	58 Neutral	HK$7.88B	46.50	4.99%	0.46%	35.01%	483.73%
1302	57 Neutral	HK$8.51B	110.67	1.98%	―	3.42%	-70.82%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9996	41 Neutral	€3.87B	-15.77	-11.20%	―	29.25%	9.02%

Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events

Beijing Chunlizhengda Medical Instruments Announces Strategic Governance Changes

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced an extraordinary general meeting scheduled for November 19, 2025, to discuss significant changes in its governance structure. The meeting will consider the abolishment of the Supervisory Committee, amendments to the Articles of Association, and changes to the rules of procedures for general and board meetings. Additionally, amendments to the working system for independent directors and management measures for the use of proceeds will be reviewed, along with the 2025 Third Quarterly Profit Distribution Plan. These proposed changes indicate a strategic shift in the company’s governance and operational procedures, potentially impacting its stakeholders and market positioning.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Proposes Governance Changes at H Shareholders’ Meeting

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a class meeting for its H shareholders to discuss and potentially approve significant changes, including the abolishment of the Supervisory Committee and amendments to the Articles of Association and procedural rules for meetings. These changes could streamline the company’s governance structure, potentially impacting its operational efficiency and strategic decision-making processes.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Proposes Governance Amendments Amid Regulatory Changes

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced proposed amendments to its Articles of Association and internal management policies to comply with recent changes in the Company Law of China and the Hong Kong Stock Exchange’s listing rules. Key changes include the abolishment of the supervisory committee, with its functions transferred to the audit committee, and alignment with the expanded paperless listing regime. These amendments, aimed at enhancing corporate governance and operational efficiency, are subject to shareholder approval at an upcoming extraordinary general meeting.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Announces Third Quarter 2025 Dividend

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced a cash dividend for the third quarter of 2025, declaring RMB 2.1 per 10 shares. The dividend, subject to shareholder approval on November 19, 2025, will be paid on January 19, 2026, with specific withholding tax rates applied to different categories of shareholders. This announcement reflects the company’s commitment to providing returns to its investors and may influence its market positioning by attracting more stakeholders.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Medical Instruments Releases Q3 2025 Financial Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. has released its unaudited financial results for the third quarter of 2025, prepared according to Chinese Accounting Standards. The report highlights the company’s financial performance over the nine months ending September 30, 2025, and advises investors to be aware of potential investment risks. The report is available in both Chinese and English, with the Chinese version taking precedence in case of discrepancies.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Medical Instruments Schedules Board Meeting for Quarterly Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced that its board of directors will meet on October 30, 2025, to approve the company’s third quarterly results for the nine months ending September 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Medical Instruments Schedules Board Meeting for Quarterly Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced that its board of directors will meet on October 30, 2025, to approve the company’s third quarterly results for the nine months ending September 30, 2025. The meeting will also consider the payment of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Reports Stable Interim Financial Results for 2025

Beijing Chunlizhengda Medical Instruments Co., Ltd. announced its unaudited consolidated interim results for the first half of 2025, showing a stable financial position with total assets amounting to RMB 3.49 billion as of June 30, 2025. The company’s current assets slightly increased, driven by a rise in held-for-trading financial assets, while its non-current assets also saw a modest increase, indicating ongoing investments in fixed assets and construction projects.

The most recent analyst rating on (HK:1858) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H stock, see the HK:1858 Stock Forecast page.

Beijing Chunlizhengda Schedules Board Meeting for Interim Results

Beijing Chunlizhengda Medical Instruments Co., Ltd. has announced that its board of directors will hold a meeting on August 29, 2025, to approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting could impact the company’s financial strategy and shareholder returns, potentially influencing its market position and stakeholder interests.